je.st
news
Tag: merck announces
Merck Animal Health Announces Appointment of Dr. Mark Engle to the Swine Technical Services Team
2014-06-19 16:05:00| National Hog Farmer
Source: Merck Animal Health Merck Animal Health today announced that Mark Engle, D.V.M, MS, has joined the company as a senior technical services manager for the Swine Business Unit. Dr. Engle received his doctor of veterinary medicine degree from Iowa State University and his master of science from the University of Minnesota. Dr. Engle has worked in private practice and swine farm management, as well as for swine genetics companies. He was most recently with the Pig Improvement Company. read more
Tags: services
health
team
mark
Merck Announces Third-Quarter 2014 Dividend
2014-05-27 18:21:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.44 per share of the companys common stock for the third quarter of 2014. Payment will be made on July 8, 2014, to stockholders of record at the close of business on June 16, 2014. About Merck Language: English Contact: MerckMedia:Lainie Keller, 908-423-4187orInvestors:Carol Ferguson, 908-423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: announces
dividend
merck
announces thirdquarter
Merck Announces FDA Acceptance for Review of MK-3475 Biologics License Application for Advanced Melanoma
2014-05-06 14:40:00| Merck.com - Corporate News
Dateline City: BOSTON Priority Review Designation for MK-3475 BLA for Proposed Indication of Unresectable or Metastatic Melanoma in Patients Who Have Been Previously Treated with Ipilimumab Advancing New Phase 3 Studies with MK-3475 in Adjuvant Melanoma, Previously-Untreated Non-Small Cell Lung Cancer, Advanced Head & Neck and Bladder Cancers Data from Studies in Three Different Cancer Types to be presented at 2014 ASCO Annual Meeting Initiating Phase 1 Study with Investigational Anti-GITR Antibody (MK-4166) BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for MK-3475, Mercks investigational anti-PD-1 antibody, for the treatment of unresectable or metastatic melanoma in patients who have been previously treated with ipilimumab. Language: English Contact: MerckMedia:Ian McConnell, 973-901-5722Claire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
review
application
license
Merck Announces Sale of Consumer Care Business to Bayer AG for $14.2 Billion
2014-05-06 12:00:00| Merck.com - Financial News
Dateline City: BOSTON Enters into Worldwide Collaboration with Bayer to Market and Develop Novel Therapies for Cardiovascular Disease Collaboration Includes a $1 Billion Up-front Payment by Merck to Bayer BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that it has entered into a definitive agreement to sell its Merck Consumer Care (MCC) business to Bayer AG (BAYRY) for $14.2 billion. Under the terms of the agreement, Bayer AG will acquire Mercks existing OTC business, including the global trademark and prescription rights for Claritin and Afrin. Language: English Contact: MerckMedia:Steve Cragle, 908-423-3461Pam Eisele, 267-305-3558orInvestors:Joe Romanelli, 908-423-5185Carol Ferguson, 908-423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: business
care
sale
consumer
Merck Announces First-Quarter 2014 Financial Results
2014-04-29 13:00:00| Merck.com - Financial News
Dateline City: WHITEHOUSE STATION, N.J. First-Quarter 2014 Non-GAAP EPS of $0.88, Excluding Certain Items; GAAP EPS of $0.57; Confirms 2014 Full-Year Non-GAAP EPS Target of $3.35 to $3.53, Excluding Certain Items; GAAP EPS Range of $2.15 to $2.47 Worldwide Sales were $10.3 Billion, a Decrease of 4 Percent, Reflecting Unfavorable Impact of Patent Expiries and a 2 Percent Unfavorable Impact from Foreign Exchange Strategic Initiatives Drove Cost Reductions and Portfolio Divestitures, Generating First-Quarter 2014 Benefits Sales of REMICADE, SIMPONI and ISENTRESS, as well as Diabetes and Vaccines Franchises Grew FDA Approved GRASTEK and RAGWITEK Sublingual Allergen Extract Immunotherapy Tablets and Accepted Filings for V503 and Suvorexant; Company Announced Progress in Key Clinical Programs Including HCV and HIV Repurchased $7.5 Billion of Common Stock Over Previous 12 Months as Part of Ongoing Share Repurchase Program WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2014. Language: English Contact: MerckMedia:Steve Cragle, 908-423-3461Lainie Keller, 908-423-4187orInvestors:Joe Romanelli, 908-423-5185Carol Ferguson, 908-423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
Sites : [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] next »